Current Rating Overview
MarketsMOJO currently assigns Lupin Ltd. a 'Buy' rating, reflecting a positive outlook on the stock's potential for investors. This rating is based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. The Mojo Score stands at 77.0, indicating a solid investment case, albeit slightly lower than the previous 'Strong Buy' grade of 80 recorded before 25 May 2026.
Quality Assessment
As of 08 June 2026, Lupin Ltd. maintains a 'good' quality grade. The company demonstrates robust fundamentals, including a conservative debt profile with an average Debt to Equity ratio of just 0.11 times. This low leverage supports financial stability and reduces risk exposure. Additionally, Lupin has shown consistent operational strength, with net sales growing at an annual rate of 13.02% and operating profit expanding at 34.70%, signalling efficient management and sustainable business growth.
Valuation Perspective
The valuation grade for Lupin Ltd. is currently 'attractive'. The stock trades at a Price to Book Value of 4.6, which, while elevated, is considered reasonable given the company's strong return on equity (ROE) of 25.7%. This suggests that Lupin is generating substantial shareholder value relative to its book value. Moreover, the stock is trading at a discount compared to its peers' average historical valuations, offering investors a favourable entry point. The PEG ratio of 0.2 further indicates that the stock's price is low relative to its earnings growth, enhancing its appeal from a valuation standpoint.
Financial Trend and Performance
The financial trend for Lupin Ltd. is rated 'very positive'. The latest data as of 08 June 2026 reveals strong profitability and growth momentum. The company reported net sales of ₹21,689.69 crores for the nine months ended March 2026, reflecting a robust growth rate of 26.78%. Net profit has surged by 24.41%, with a profit after tax (PAT) of ₹4,544.71 crores for the same period. Return on capital employed (ROCE) reached a high of 27.06% in the half year, underscoring efficient capital utilisation. Lupin has also declared positive results for four consecutive quarters, signalling consistent operational performance and earnings stability.
Technical Analysis
From a technical standpoint, Lupin Ltd. is rated as 'mildly bullish'. The stock has experienced some short-term volatility, with a one-day decline of 0.35% and a one-month dip of 4.95%. However, over longer periods, the stock has shown resilience, delivering a 6-month gain of 9.11%, a year-to-date return of 7.01%, and a one-year return of 13.35%. These figures suggest that while there may be intermittent fluctuations, the overall trend remains positive, supporting the 'Buy' rating.
Institutional Confidence
Institutional investors hold a significant 47.03% stake in Lupin Ltd., reflecting strong confidence from knowledgeable market participants. Such high institutional ownership often correlates with thorough fundamental analysis and long-term commitment, which can provide stability to the stock price and reduce volatility.
Implications for Investors
For investors, the 'Buy' rating on Lupin Ltd. suggests that the stock is expected to outperform the broader market over the medium term. The combination of solid quality metrics, attractive valuation, positive financial trends, and supportive technical signals provides a compelling investment case. However, investors should remain mindful of sector-specific risks and market conditions that could impact performance.
Here's How Lupin Ltd. Looks Today
As of 08 June 2026, Lupin Ltd. stands as a midcap pharmaceutical and biotechnology company with a market capitalisation befitting its sector stature. The company’s financial health is underscored by strong growth in net sales and profits, alongside efficient capital deployment. Its valuation metrics indicate that the stock is reasonably priced relative to its earnings growth and peer group, making it an attractive option for investors seeking exposure to the pharmaceuticals sector.
The stock’s recent performance shows resilience despite short-term corrections, with a positive return trajectory over the past year. The technical mild bullishness suggests that the stock could continue to benefit from upward momentum, supported by strong fundamentals and institutional backing.
Just made the cut! This Mid Cap from the Heavy Electrical Equipment sector entered our elite Top 1% list recently. Discover it before the crowd catches on!
- - Top-rated across platform
- - Strong price momentum
- - Near-term growth potential
Sector and Market Context
Lupin Ltd. operates within the Pharmaceuticals & Biotechnology sector, a space characterised by innovation, regulatory challenges, and steady demand driven by healthcare needs. The company’s ability to sustain growth and profitability amid competitive pressures and evolving market dynamics is a testament to its operational strength and strategic positioning.
Compared to sector peers, Lupin’s valuation remains attractive, and its financial metrics outperform many competitors. This relative strength is a key factor supporting the current 'Buy' rating, as it indicates potential for continued market share gains and earnings expansion.
Conclusion
In summary, Lupin Ltd.’s 'Buy' rating by MarketsMOJO, last updated on 25 May 2026, reflects a balanced and positive outlook based on current data as of 08 June 2026. The company’s strong quality fundamentals, attractive valuation, very positive financial trends, and mildly bullish technical indicators combine to make it a compelling choice for investors seeking growth in the pharmaceutical sector. While short-term price fluctuations may occur, the overall investment thesis remains robust, supported by consistent earnings growth and institutional confidence.
Investors considering Lupin Ltd. should weigh these factors carefully and monitor ongoing sector developments to capitalise on the stock’s potential while managing risks prudently.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
